Preclinical lead development of ADAM10 enhancing molecules for the treatment of Alzheimer's dementia

Research unit

INNOSUISSE

Project number

119.341 IP-LS

Project title

Preclinical lead development of ADAM10 enhancing molecules for the treatment of Alzheimer's dementia

Texts for this project

	German	French	Italian	English
Key words	-	-	-
Abstract	-	-	-

Category	Text
Key words (English)	Life sciences, Pharmaceuticals
Abstract (English)	Abnormal processing of amyloid precursor protein (APP) and accumulation of amyloid-beta peptides is a hallmark of Alzheimer's dementia. The protease ADAM10 neuroprotectively cleaves APP, blocking the accumulation of amyloid-beta peptides. We aim to develope molecules to enhance ADAM10 activity.